EVALUATION OF ANTI-ASTHMATIC ACTIVITY OF MENISAMOOLA PARPAM IN HISTAMINE-INDUCED BRONCHIAL ASTHMA MODEL IN WISTAR RATS
International Journal of Pharmaceutics and Drug Analysis · 30.06.2026 · 70
DOI: 10.47957/ijpda.v14i2.738 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Pharmaceutics and Drug Analysis, online erschienen am 30.06.2026. Verfasst von Kowsalya T und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Bronchial asthma is a chronic inflammatory disorder of the respiratory system characterized by airway hyperresponsiveness, eosinophilia, and elevated immunoglobulin E (IgE) levels. Although conventional therapies are effective, their long-term use may be associated with adverse effects. Traditional Siddha formulations offer a potential alternative approach for the management of respiratory diseases.
Objective
To evaluate the anti-asthmatic activity of Menisamoola Parpam (MSP) using a histamine-induced bronchial asthma model in Wistar rats. Materials and Methods: Wistar rats were divided into five groups: normal control, disease control, standard (mepyramine-treated), and MSP-treated groups receiving low and high doses. Bronchial asthma was induced by exposure to 0.5% histamine aerosol, and the pre-convulsion time was recorded. Haematological parameters, including total leukocyte count and eosinophil count, were evaluated. Serum IgE levels and the concentrations of inflammatory cytokines (TNF-?, IL-4, and IL-5) in bronchoalveolar lavage fluid were determined using enzyme-linked immunosorbent assay (ELISA). Mast cell stabilization activity and histopathological examination of lung tissues were also performed. Statistical analysis was conducted using one-way analysis of variance (ANOVA) followed by Dunnett's post hoc test.
Results
MSP significantly reduced total leukocyte and eosinophil counts, serum IgE levels, and the concentrations of pro-inflammatory cytokines compared with the disease control group. MSP also exhibited dose-dependent inhibition of mast cell degranulation. Histopathological examination revealed reduced inflammatory cell infiltration and restoration of normal lung architecture in the MSP-treated groups.
Conclusion
Menisamoola Parpam demonstrated significant anti-asthmatic activity through its anti-inflammatory, immunomodulatory, and mast cell-stabilizing effects. These findings suggest that MSP has potential as a therapeutic agent for the management of bronchial asthma.
Zitieren
APA
T, K., R, S., & K, S. (2026). EVALUATION OF ANTI-ASTHMATIC ACTIVITY OF MENISAMOOLA PARPAM IN HISTAMINE-INDUCED BRONCHIAL ASTHMA MODEL IN WISTAR RATS. International Journal of Pharmaceutics and Drug Analysis, 70. https://doi.org/10.47957/ijpda.v14i2.738
Vancouver
T K, R S, K S. EVALUATION OF ANTI-ASTHMATIC ACTIVITY OF MENISAMOOLA PARPAM IN HISTAMINE-INDUCED BRONCHIAL ASTHMA MODEL IN WISTAR RATS. International Journal of Pharmaceutics and Drug Analysis. 2026:70. doi:10.47957/ijpda.v14i2.738
BibTeX
@article{T2026,
author = {T, Kowsalya and R, Sasirekha and K, Sudhamathi},
title = {EVALUATION OF ANTI-ASTHMATIC ACTIVITY OF MENISAMOOLA PARPAM IN HISTAMINE-INDUCED BRONCHIAL ASTHMA MODEL IN WISTAR RATS},
journal = {International Journal of Pharmaceutics and Drug Analysis},
year = {2026},
pages = {70},
doi = {10.47957/ijpda.v14i2.738}
}
EUVIMED